TY - JOUR
T1 - 'Long term evaluation of combined treatment of Parkinson disease with L-Dopa, peripheral decarboxylase inhibitors and bromocriptine'
AU - Caraceni, T.
AU - Giovannini, P.
AU - Girotti, F.
AU - Parati, E.
AU - Pederzoli, M.
AU - Scigliano, G.
PY - 1981
Y1 - 1981
N2 - In this study, the authors' experience of Parkinson Disease treatment with longterm bromocriptine (Br) administration, is summarized. Br, which acts directly on dopaminergic receptors, was introduced in combination with L-Dopa and peripheral decarboxylase inhibitors (PDI). The reasons for this association were: the reduced effectiveness of the current treatment (L-Dopa+PDI), onset of AIM (abnormal involuntary movements), and the patient's desire to try new drugs. Only the patients who had been on the triple association for at least a year were considered. Therefore, of 50 patients originally considered, only 19 were included in this study. The addition of Br allowed a reduction of the mean daily dose of L-Dopa (30%) and the therapeutic efficacy of the drug remained unchanged even after more than 4 years treatment. The 'on-off' effect and AIM, are reduced by Br, especially in the first months of treatment. The triple association is regarded at present as the best treatment for Parkinson disease.
AB - In this study, the authors' experience of Parkinson Disease treatment with longterm bromocriptine (Br) administration, is summarized. Br, which acts directly on dopaminergic receptors, was introduced in combination with L-Dopa and peripheral decarboxylase inhibitors (PDI). The reasons for this association were: the reduced effectiveness of the current treatment (L-Dopa+PDI), onset of AIM (abnormal involuntary movements), and the patient's desire to try new drugs. Only the patients who had been on the triple association for at least a year were considered. Therefore, of 50 patients originally considered, only 19 were included in this study. The addition of Br allowed a reduction of the mean daily dose of L-Dopa (30%) and the therapeutic efficacy of the drug remained unchanged even after more than 4 years treatment. The 'on-off' effect and AIM, are reduced by Br, especially in the first months of treatment. The triple association is regarded at present as the best treatment for Parkinson disease.
UR - http://www.scopus.com/inward/record.url?scp=0019771856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019771856&partnerID=8YFLogxK
M3 - Article
C2 - 7333824
AN - SCOPUS:0019771856
VL - 2
SP - 337
EP - 342
JO - Italian Journal of Neurological Sciences
JF - Italian Journal of Neurological Sciences
SN - 0392-0461
IS - 4
ER -